Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy

IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. A challenge for evaluating treatments for IgAN is the usual long time course for progression to ESKD. The aim of this Kidney Health Initiative project was to identify surrogate end points that could serve...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin J Am Soc Nephrol
Auteurs principaux: Thompson, Aliza, Carroll, Kevin, A. Inker, Lesley, Floege, Jürgen, Perkovic, Vlado, Boyer-Suavet, Sonia, W. Major, Rupert, I. Schimpf, Judith, Barratt, Jonathan, Cattran, Daniel C., S. Gillespie, Barbara, Kausz, Annamaria, W. Mercer, Alex, Reich, Heather N., H. Rovin, Brad, West, Melissa, Nachman, Patrick H.
Format: Artigo
Langue:Inglês
Publié: American Society of Nephrology 2019
Sujets:
Feature
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6419287/
https://ncbi.nlm.nih.gov/pubmed/30635299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.08600718
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires